相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cell death cascade and molecular therapy in ADAR2-deficient motor neurons of ALS
Takenari Yamashita et al.
NEUROSCIENCE RESEARCH (2019)
Severe Aggression After Perampanel Overdose: Case Report
Carrie C. Wu et al.
PSYCHOSOMATICS (2019)
Efficacy and safety of perampanel in Parkinson's disease. A systematic review with meta-analysis
Simona Lattanzi et al.
JOURNAL OF NEUROLOGY (2018)
C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity
Bhuvaneish T. Selvaraj et al.
NATURE COMMUNICATIONS (2018)
Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings
J. -J. Tsai et al.
ACTA NEUROLOGICA SCANDINAVICA (2018)
Deficient RNA-editing enzyme ADAR2 in an amyotrophic lateral sclerosis patient with a FUSP525L mutation
Hitoshi Aizawa et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2016)
Cognitive impairment, behavioral impairment, depression, and wish to die in an ALS cohort
Judith Rabkin et al.
NEUROLOGY (2016)
Inhibition of calcium-permeable and calcium-impermeable AMPA receptors by perampanel in rat brain neurons
Oleg I. Barygin
NEUROSCIENCE LETTERS (2016)
The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice
Megumi Akamatsu et al.
SCIENTIFIC REPORTS (2016)
Cognitive-behavioral changes in amyotrophic lateral sclerosis: Screening prevalence and impact on patients and caregivers
Meredith Bock et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2016)
FUS regulates AMPA receptor function and FTLD/ALS-associated behaviour via GluA1 mRNA stabilization
Tsuyoshi Udagawa et al.
NATURE COMMUNICATIONS (2015)
The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
H. Blasco et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Adverse effects and safety profile of perampanel: A review of pooled data
Fergus Rugg-Gunn
EPILEPSIA (2014)
Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial
Merit E. Cudkowicz et al.
LANCET NEUROLOGY (2014)
Perampanel Inhibition of AMPA Receptor Currents in Cultured Hippocampal Neurons
Chao-Yin Chen et al.
PLOS ONE (2014)
Mechanism of Inhibition of the GluA2 AMPA Receptor Channel Opening by Talampanel and Its Enantiomer: The Stereochemistry of the 4-Methyl Group on the Diazepine Ring of 2,3-Benzodiazepine Derivatives
Congzhou Wang et al.
ACS CHEMICAL NEUROSCIENCE (2013)
Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist
M. A. Rogawski et al.
ACTA NEUROLOGICA SCANDINAVICA (2013)
Discovery of 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (Perampanel): A Novel, Noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic Acid (AMPA) Receptor Antagonist
Shigeki Hibi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus
Laura Ceolin et al.
NEUROCHEMISTRY INTERNATIONAL (2012)
A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology
Takenari Yamashita et al.
NATURE COMMUNICATIONS (2012)
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Robert G. Miller et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
How common are behavioural changes in amyotrophic lateral sclerosis?
Patricia Lillo et al.
AMYOTROPHIC LATERAL SCLEROSIS (2011)
Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically
Melinda Paizs et al.
AMYOTROPHIC LATERAL SCLEROSIS (2011)
A Review of the Neural Mechanisms of Action and Clinical Efficiency of Riluzole in Treating Amyotrophic Lateral Sclerosis: What have we Learned in the Last Decade?
Mark C. Bellingham
CNS NEUROSCIENCE & THERAPEUTICS (2011)
Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy
Takahisa Hanada et al.
EPILEPSIA (2011)
TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2
Hitoshi Aizawa et al.
ACTA NEUROPATHOLOGICA (2010)
A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis
Robert M. Pascuzzi et al.
AMYOTROPHIC LATERAL SCLEROSIS (2010)
Guidelines for preclinical animal research in ALS/MND: A consensus meeting
Albert C. Ludolph et al.
AMYOTROPHIC LATERAL SCLEROSIS (2010)
Induced Loss of ADAR2 Engenders Slow Death of Motor Neurons from Q/R Site-Unedited GluR2
Takuto Hideyama et al.
JOURNAL OF NEUROSCIENCE (2010)
Glutamate AMPA receptors change in motor neurons of SOD1(G93A) transgenic mice and their inhibition by a noncompetitive antagonist ameliorates the progression of amytrophic lateral sclerosis-like disease
M Tortarolo et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2006)
Novel α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonists of 2,3-benzodiazepine type:: Chemical synthesis, in vitro characterization, and in vivo prevention of acute neurodegeneration
B Elger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Molecular pharmacology of topiramate: Managing seizures and preventing migraine
HS White
HEADACHE (2005)
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
JD Rothstein et al.
NATURE (2005)
Cu/Zn-superoxide dismutase (GLY93→ALA) mutation alters AMPA receptor subunit expression and function and potentiates kainate-mediated toxicity in motor neurons in culture
A Spalloni et al.
NEUROBIOLOGY OF DISEASE (2004)
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis
ME Cudkowicz et al.
NEUROLOGY (2003)
The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis
P Van Damme et al.
NEUROSCIENCE LETTERS (2003)
Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2
M Higuchi et al.
NATURE (2000)
分享论文
